ACM
WHWK

ADAR1 Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

ADAR1 Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$443K Buy
128,503
+50,910
+66% +$159K 0.03% 212
2025
Q4 		$188K Buy
+77,593
New +$178K 0.01% 231

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

ADAR1 Capital Management's WHWK Position: Q1 2026 in Review

ADAR1 Capital Management increased its Whitehawk Therapeutics (WHWK) stake by 66% in Q1 2026, buying an estimated $159K and bringing the position to 128,503 shares worth $443K. The position accounts for 0.03% of the portfolio, ranked #212.

ADAR1 Capital Management first reported a position in WHWK in Q4 2025 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • ADAR1 Capital Management held 128,503 shares of Whitehawk Therapeutics worth $443K as of Q1 2026.
  • ADAR1 Capital Management bought 50,910 Whitehawk Therapeutics shares in Q1 2026, an estimated $159K.
  • Whitehawk Therapeutics made up 0.03% of ADAR1 Capital Management's portfolio in Q1 2026, its #212 holding.
  • ADAR1 Capital Management first reported a position in Whitehawk Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.